CD274 and myelodysplastic syndrome: However, a phase Ib trial on atezolizumab, the only PD-L1 antibody that was examined as a monotherapy agent in MDS patients following HMA failure, reported 70% (7/10) of patients did not survive after a 160-day median follow-up, mainly due to disease progression [129].